UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis

Blood, 2023-06, Vol.141 (25), p.3078-3090

2023

Volltextzugriff (PDF)

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

Blood, 2018-09, Vol.132 (12), p.1304-1317

2018

Volltextzugriff (PDF)

Pregnancy exposure to midostaurin in the first trimester

Annals of hematology, 2020-02, Vol.99 (2), p.355-356

2020

Volltextzugriff (PDF)

Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group

Clinical and experimental medicine, 2023-12, Vol.23 (8), p.4199-4217

2023

Volltextzugriff (PDF)

Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis

Nature cell biology, 2022-06, Vol.24 (6), p.928-939

2022

Volltextzugriff (PDF)

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

EJHaem, 2023-11, Vol.4 (4), p.1013-1018

2023

Volltextzugriff (PDF)

Immunotherapy in Multiple Myeloma

Cells (Basel, Switzerland), 2020-03, Vol.9 (3), p.601

2020

Volltextzugriff (PDF)

Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers

PharmacoEconomics - open, 2024-09, Vol.8 (5), p.651-664

2024

Volltextzugriff (PDF)

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Blood, 2011-04, Vol.117 (17), p.4409-4419

2011

Volltextzugriff (PDF)

Immunoglobulin M Monoclonal Gammopathies of Clinical Significance

Frontiers in oncology, 2022-06, Vol.12, p.905484-905484

2022

Volltextzugriff (PDF)

Multiple Myeloma: Case of a "Moving" Sternal Wire

Diagnostics (Basel), 2023-06, Vol.13 (12), p.2082

2023

Volltextzugriff (PDF)

Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms

Asian Pacific Journal of Cancer Prevention, 2020-09, Vol.21 (9), p.2805-2810

2020

Volltextzugriff (PDF)

Immunoglobulin M Paraproteinaemias

Cancers, 2020-06, Vol.12 (6), p.1688

2020

Volltextzugriff (PDF)

Potential Clinical Application of Genomics in Multiple Myeloma

International journal of molecular sciences, 2018-06, Vol.19 (6), p.1721

2018

Volltextzugriff (PDF)

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

Cancer research (Chicago, Ill.), 2009-07, Vol.69 (14), p.5835-5842

2009

Volltextzugriff (PDF)

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

Cancer chemotherapy and pharmacology, 2013-05, Vol.71 (5), p.1357-1368

2013

Volltextzugriff (PDF)

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Cancers, 2022-07, Vol.14 (15), p.3576

2022

Volltextzugriff (PDF)

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

Clinical cancer research, 2009-12, Vol.15 (23), p.7153-7160

2009

Volltextzugriff (PDF)

Risk Stratification in Multiple Myeloma

Current hematologic malignancy reports, 2016-04, Vol.11 (2), p.137-147

2016

Volltextzugriff (PDF)

Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis

Clinical lymphoma, myeloma and leukemia, 2019-08, Vol.19 (8), p.e470-e477

2019

Volltextzugriff (PDF)

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma

Haematologica (Roma), 2011-08, Vol.96 (8), p.1170-1179

2011

Volltextzugriff (PDF)

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma

Blood cancer journal (New York), 2021-02, Vol.11 (2), p.32-32, Article 32

2021

Volltextzugriff (PDF)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma

Cancers, 2020-07, Vol.12 (7), p.1759

2020

Volltextzugriff (PDF)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Blood cancer journal (New York), 2021-09, Vol.11 (9), p.150-150, Article 150

2021

Volltextzugriff (PDF)

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

PloS one, 2011-07, Vol.6 (7), p.e20226

2011

Volltextzugriff (PDF)

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(130)

Publikationsform

Sprache

Englisch
(151)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis

Pregnancy exposure to midostaurin in the first trimester

Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group

Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Immunotherapy in Multiple Myeloma

Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

Immunoglobulin M Monoclonal Gammopathies of Clinical Significance

Multiple Myeloma: Case of a "Moving" Sternal Wire

Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms

Immunoglobulin M Paraproteinaemias

Potential Clinical Application of Genomics in Multiple Myeloma

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

Real-World Experience of Measurable Residual Disease Response and Prognosis in Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Interactions of the Hdm2/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib

Risk Stratification in Multiple Myeloma

Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation

Suchergebnisse filtern